

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 5 mg/ml solution for injection for cattle and pigs

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

### **Active substance:**

Meloxicam 5 mg

### **Excipient(s):**

Benzyl alcohol 50 mg

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Solution for injection.

Clear, greenish yellow solution.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Cattle (calves and young cattle) and pigs.

### **4.2 Indications for use, specifying the target species**

#### Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For the relief of post-operative pain following dehorning in calves.

#### Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For the relief of post operative pain associated with minor soft tissue surgery such as castration.

### **4.3 Contraindications**

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

Do not use in pigs less than 2 days old.

#### **4.4 Special warnings for each target species**

Treatment of calves with Melovem 20 minutes before dehorning reduces post-operative pain. Melovem alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Treatment of piglets with Melovem before castration reduces post operative pain. To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative is needed.

To obtain the best possible pain relieving effect post surgery Melovem should be administered 30 minutes before surgical intervention.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

Transient swelling at the injection site was commonly reported in clinical studies following subcutaneous administration in cattle. Injection site swelling may be painful.

Transient swelling at the injection site was observed in clinical studies following intramuscular administration in pigs.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

##### Cattle:

Can be used during pregnancy.

For lactating animals see section 4.11.

##### Pigs:

Can be used during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

## 4.9 Amounts to be administered and administration route

### Cattle:

Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10.0 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

### Pigs:

#### Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/25 kg body weight). If required, a second administration of meloxicam can be given after 24 hours.

It is recommended to administer the second injection at a different site since local tolerance has been assessed after single injection only.

#### Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.

Avoid introduction of contamination during use.

## 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In the case of overdosage symptomatic treatment should be initiated.

## 4.11 Withdrawal periods

### Cattle:

Meat and offal: 15 days.

Not authorised for use in animals producing milk for human consumption.

### Pigs:

Meat and offal: 5 days.

## 5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams)  
ATCvet code: QM01AC06.

### 5.1 Pharmacodynamic properties

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic properties. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by *E. coli* endotoxin administration in calves and pigs.

### 5.2 Pharmacokinetic particulars

#### Absorption

After a single subcutaneous dose of 0.5 mg meloxicam/kg, C<sub>max</sub> values of 2.1 µg/ml were reached after 7.7 hours in young cattle.

Following single intramuscular doses of 0.4 mg meloxicam/kg, a C<sub>max</sub> value of 1.1 to 1.5 µg/ml was reached within 1 hour in pigs.

### Distribution

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

### Metabolism

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

### Elimination

Meloxicam is eliminated with a half-life of 26 hours after subcutaneous injection in young cattle.

In pigs, after intramuscular administration, the mean plasma biological elimination half-life is approximately 2.5 hours.

Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Benzyl alcohol  
Hydrochloric acid  
Sodium chloride  
Macrogol 400  
Macrogol 1500  
Meglumine  
Water for injection

### **6.2 Incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the immediate packaging: 28 days.

### **6.4 Special precautions for storage**

Keep injection vial in the outer carton in order to protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

### **6.5 Nature and composition of immediate packaging**

Cardboard box with 1 colourless, type I glass injection vial of 100 ml, which is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

**6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer The Netherlands

**8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/001

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 07-07-2009

Date of last renewal: 06-06-2014

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 20 mg/ml solution for injection for cattle, pigs and horses

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

**Active substance:**

Meloxicam 20 mg

**Excipient(s):**

Ethanol 150 mg

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Solution for injection.

Clear yellow solution.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Cattle, pigs and horses

### 4.2 Indications for use, specifying the target species

Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxemia (mastitis-metritisagalactia syndrome) with appropriate antibiotic therapy.

Horses:

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

### 4.3 Contraindications

See also section 4.7.

Do not use in horses less than 6 weeks of age.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

#### **4.4 Special warnings for each target species**

Treatment of calves with Melovem 20 minutes before dehorning reduces post-operative pain. Melovem alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAID) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

In horses, a transient swelling at the injection site can occur but resolves without intervention.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)

#### **4.7 Use during pregnancy, lactation or lay**

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: Do not use in pregnant or lactating mares.

See also section 4.3.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

#### **4.9 Amounts to be administered and administration route**

##### Cattle:

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

##### Pigs:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

##### Horses:

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3.0 ml/100 kg body weight).

Avoid introduction of contamination during use.

When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. The maximum number of broachings should be limited to 20.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In the case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

##### Cattle:

Meat and offal: 15 days

Milk: 5 days

##### Pigs:

Meat and offal: 5 days

##### Horses:

Meat and offal: 5 days

Not authorised to use in horses producing milk for human consumption.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams)

ATCvet code: QM01AC06.

#### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by *E. coli* endotoxin administration in calves, lactating cows and pigs.

## **5.2 Pharmacokinetic particulars**

### Absorption

After a single subcutaneous dose of 0.5 mg meloxicam/kg,  $C_{max}$  values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.

After two intramuscular doses of 0.4 mg meloxicam/kg, a  $C_{max}$  value of 1.9 µg/ml was reached after 1 hour in pigs.

### Distribution

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

### Metabolism

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. The metabolism in horses has not been investigated.

### Elimination

Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.

In pigs, after intramuscular administration, the mean plasma biological elimination half-life is approximately 2.5 hours.

In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours.

Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Ethanol  
Glycine  
Hydrochloric acid/sodium hydroxide  
Macrogol 300  
Meglumine  
Poloxamer 188  
Sodium citrate  
Water for injection

### **6.2 Incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.

Shelf life after first opening the immediate packaging: 28 days.

### **6.4. Special precautions for storage**

Keep injection vial in the outer carton in order to protect from light.  
Do not refrigerate or freeze. Protect from frost.

#### **6.5 Nature and composition of immediate packaging**

Cardboard box with 1 colourless, type I glass injection vial of 50 ml, 100 ml and 250 ml closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

#### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

### **7. MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

### **8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/002  
EU/2/09/098/003  
EU/2/09/098/004

### **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 07-07-2009  
Date of last renewal: 06-06-2014

### **10 DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

### **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 30 mg/ml solution for injection for cattle and pigs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

### Active substance:

Meloxicam 30 mg

### Excipient(s):

Benzyl alcohol 20 mg

N-methyl pyrrolidone 200 mg

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Solution for injection.

Clear yellow solution.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Cattle and pigs

### 4.2 Indications for use, specifying the target species

#### Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

#### Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritisagalactia syndrome) with appropriate antibiotic therapy.

### 4.3 Contraindications

See also section 4.7.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

#### **4.4 Special warnings for each target species**

Treatment of calves with Melovem 20 minutes before dehorning reduces post-operative pain. Melovem alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAID) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Women of childbearing age, pregnant women or women suspected of being pregnant should use the veterinary medicinal product with serious caution to avoid accidental self-injection.

#### **4.6 Adverse reactions (frequency and seriousness)**

In cattle and pigs, subcutaneous as well as intramuscular administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)

#### **4.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established in cattle and pigs during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Use only according to the benefit-risk assessment by the responsible veterinarian.

See also section 4.3.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

#### **4.9 Amounts to be administered and administration route**

Cattle:

Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/150 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

Pigs:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/150 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

Avoid introduction of contamination during use.

When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. The maximum number of broachings should be limited to 20.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In the case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

Cattle:

Meat and offal: 15 days.

Milk: 5 days.

Pigs:

Meat and offal: 5 days.

## **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams)  
ATCvet code: QM01AC06.

### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by *E. coli* endotoxin administration in calves, lactating cows and pigs.

### **5.2 Pharmacokinetic particulars**

Absorption

After a single subcutaneous dose of 0.5 mg meloxicam/kg, C<sub>max</sub> values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.

After two intramuscular doses of 0.4 mg meloxicam/kg, a C<sub>max</sub> value of 1.9 µg/ml was reached after 1 hour in pigs.

Distribution

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

Metabolism

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product

in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

#### Elimination

Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.

In pigs, after intramuscular administration, the mean plasma biological elimination half-life is approximately 2.5 hours.

Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Benzyl alcohol  
Hydrochloric acid/sodium hydroxide  
Macrogol 1500  
Meglumine  
N-Methyl pyrrolidone  
Water for injection

### **6.2 Incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.

Shelf life after first opening the immediate packaging: 28 days.

### **6.4. Special precautions for storage**

This veterinary medicinal product does not require any special temperature storage conditions.

### **6.5 Nature and composition of immediate packaging**

Cardboard box with 1 colourless, type I glass injection vial of 50 ml, 100 ml and 250 ml closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

**8.       MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/005

EU/2/09/098/006

EU/2/09/098/007

**9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 07-07-2009

Date of last renewal: 06-06-2014

**10      DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 15 mg/ml oral suspension for horses

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

### **Active substance:**

Meloxicam 15 mg

### **Excipient:**

Sodium benzoate 1.5 mg

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Oral suspension.

Yellow, aqueous suspension.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Horses.

### **4.2 Indications for use, specifying the target species**

Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.

### **4.3 Contraindications**

Do not use in pregnant or lactating mares.

Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in horses less than 6 weeks of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### **4.4 Special warnings for each target species**

None.

### **4.5 Special precautions for use**

#### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of renal toxicity.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

#### **4.6 Adverse reactions (frequency and seriousness)**

Diarrhoea, typically associated with non-steroidal anti-inflammatory drugs (NSAIDs), was very rarely observed in clinical trials. The clinical sign was reversible.

Loss of appetite, lethargy, abdominal pain, colitis and urticaria have been reported very rarely from post-marketing safety experience.

Anaphylactoid reactions, which may be serious (including fatal), have been observed very rarely from post-marketing safety experience and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1 000 animals treated)
- rare (more than 1 but less than 10 animals in 10 000 animals treated)
- very rare (less than 1 animal in 10 000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Laboratory studies in cattle have not provided any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore the use in this species is not recommended during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

#### **4.9 Amounts to be administered and administration route**

To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 4 ml/100 kg body weight), once daily, up to 14 days.

In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding.

The suspension should be given using the measuring syringe provided in the package. The syringe has a kg-body weight scale.

Shake well before use.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

Avoid introduction of contamination during use.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

Meat and offal: 3 days.

Not authorised for use in animals producing milk for human consumption.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams)  
ATCvet code: QM01AC06.

#### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by *E. coli* endotoxin administration in calves and pigs.

#### **5.2 Pharmacokinetic particulars**

##### Absorption

When the product is used according to the recommended dosage regime the oral bioavailability is approximately 98 %. Maximal plasma concentrations are obtained after approximately 2–3 hours. The accumulation factor of 1.08 suggests that meloxicam does not accumulate when administered daily.

##### Distribution

Approximately 98% of meloxicam is bound to plasma proteins. The volume of distribution is 0.12 l/kg.

##### Metabolism

The metabolism is qualitatively similar in rats, mini-pigs, humans, cattle and pigs although quantitatively there are differences. The major metabolites found in all species were the 5-hydroxy- and 5-carboxymetabolites and the oxalyl-metabolite. The metabolism in horses has not been investigated. All major metabolites have been shown to be pharmacologically inactive.

##### Elimination

Meloxicam is eliminated with a terminal half-life of 7.7 hours.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Sodium benzoate

Sorbitol

Glycerol

Saccharin sodium

Xylitol

Silica, colloidal anhydrous

Hydroxyethylcellulose

Citric acid

Honey aroma

Water purified

#### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 6 months.

### **6.4. Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

After first opening, store below 25 °C.

### **6.5 Nature and composition of immediate packaging**

White, rectangular high density polyethylene bottles of 250 ml or 500 ml of product with a narrow mouth opening, closed with a white polypropylene screw cap, and provided with a polypropylene transparent lid with space to include a polypropylene measuring syringe with a synthetic rubber piston. Cardboard box with 1 white, round high-density polyethylene bottle of 100 ml of product closed with a white polypropylene screw cap and 1 polypropylene measuring syringe with a synthetic rubber piston.

Not all pack sizes may be marketed

### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/008

EU/2/09/098/009

EU/2/09/098/010

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 07-07-2009

Date of last renewal: 06-06-2014

## **10 DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMA) <https://www.emea.europa.eu/>.

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

**ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

**A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer responsible for batch release

Dopharma B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Veterinary medicinal product subject to prescription.

**C. STATEMENT OF THE MRLs**

The active substance in Melovem is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:

Pharmacologically active substance	Marker residue	Animal species	MRL	Target tissues	Other provisions	Therapeutic classification
Meloxicam	Meloxicam	Bovine, caprine, porcine, rabbit, Equidae	20 µg/kg 65 µg/kg 65 µg/kg	Muscle Liver Kidney	NO ENTRY	Antiinflammatory agents/ Non-steroidal antiinflammatory agents
		Bovine, caprine	15 µg/kg	Milk		

The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 5 mg/ml solution for injection for cattle and pigs.

Meloxicam

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Meloxicam 5 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

100 ml

**5. TARGET SPECIES**

Cattle (calves and young cattle) and pigs

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle: subcutaneous use

Pigs: intramuscular use

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Cattle: meat and offal: 15 days.

Not authorised for use in animals producing milk for human consumption.

Pigs: meat and offal: 5 days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once broached, use within 28 days.

**11. SPECIAL STORAGE CONDITIONS**

Keep the injection vial in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer - NL

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/001

**17. MANUFACTURER’S BATCH NUMBER**

Lot: {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

Glass vial

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 5 mg/ml solution for injection for cattle and pigs.

Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCE**

Meloxicam 5 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

100 ml

**5. TARGET SPECIES**

Cattle (calves and young cattle) and pigs

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD(S) AND ROUTES OF ADMINISTRATION**

Cattle: SC

Pigs: IM

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Cattle: meat and offal: 15 days.

Not permitted for use in lactating animals producing milk for human consumption.

Pigs: meat and offal: 5 days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP: {month/year}  
Once broached, use by...

**11. SPECIAL STORAGE CONDITIONS**

Keep the injection vial in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer - NL

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/001

**17. MANUFACTURER’S BATCH NUMBER**

Lot: {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 20 mg/ml solution for injection for cattle, pigs and horses  
Meloxicam

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Meloxicam 20 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

50 ml  
100 ml  
250 ml

**5. TARGET SPECIES**

Cattle, pigs and horses

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle: Subcutaneous or intravenous use  
Pigs: Intramuscular use  
Horses: Intravenous use  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Withdrawal period:  
Cattle: meat and offal: 15 days; milk: 5 days  
Pigs, horses: meat and offal: 5 days  
Not authorised to use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once broached use within 28 days.

**11. SPECIAL STORAGE CONDITIONS**

Keep the vial in the outer carton in order to protect from light.

Do not refrigerate or freeze. Protect from frost.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/002 (50 ml)  
EU/2/09/098/003 (100 ml)  
EU/2/09/098/004 (250 ml)

**17. MANUFACTURER'S BATCH NUMBER**

Lot: {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

Glass vial 100 ml and 250 ml

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 20 mg/ml solution for injection for cattle, pigs and horses  
Meloxicam

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Meloxicam 20 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

100 ml  
250 ml

**5. TARGET SPECIES**

Cattle, pigs and horses

**6. INDICATIONS**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle: SC or IV  
Pigs: IM  
Horses: IV  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Withdrawal period:  
Cattle: meat and offal: 15 days; milk: 5 days  
Pigs, horses: meat and offal: 5 days  
Not authorised to use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}  
Once broached use by...

**11. SPECIAL STORAGE CONDITIONS**

Keep the vial in the outer carton in order to protect from light.  
Do not refrigerate or freeze. Protect from frost.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/003 (100 ml)  
EU/2/09/098/004 (250 ml)

**17. MANUFACTURER’S BATCH NUMBER**

Lot: {number}

**PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

Glass vial 50 ml

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 20 mg/ml solution for injection for cattle, pigs and horses

Meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 20 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

50 ml

**4. ROUTE(S) OF ADMINISTRATION**

Cattle: SC or IV

Pigs: IM

Horses: IV

**5. WITHDRAWAL PERIOD**

Withdrawal period:

Cattle: meat and offal: 15 days; milk: 5 days

Pigs, horses: meat and offal: 5 days

Not authorised for use in horses producing milk for human consumption.

**6. BATCH NUMBER**

Lot: {number}

**7. EXPIRY DATE**

EXP: {month/year}

Once broached use by...

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 30 mg/ml solution for injection for cattle and pigs  
Meloxicam

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Meloxicam 30 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

50 ml  
100 ml  
250 ml

**5. TARGET SPECIES**

Cattle and pigs

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle: Subcutaneous use  
Pigs: Intramuscular use  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Withdrawal period:  
Cattle: meat and offal: 15 days; milk: 5 days.  
Pigs: meat and offal: 5 days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once broached use within 28 days.

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/005 (50 ml)  
EU/2/09/098/006 (100 ml)  
EU/2/09/098/007 (250 ml)

**17. MANUFACTURER’S BATCH NUMBER**

Lot: {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

Glass vial 100 ml and 250 ml

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 30 mg/ml solution for injection for cattle and pigs.

Meloxicam

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Meloxicam 30 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

100 ml

250 ml

**5. TARGET SPECIES**

Cattle and pigs

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle: SC

Pigs: IM

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Withdrawal period:

Cattle: meat and offal: 15 days; milk: 5 days.

Pigs: meat and offal: 5 days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}  
Once broached use by...

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/006 (100 ml)  
EU/2/09/098/007 (250 ml)

**17. MANUFACTURER’S BATCH NUMBER**

Lot: {number}

**PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Glass vial 50 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 30 mg/ml solution for injection for cattle and pigs  
Meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 30 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

50 ml

**4. ROUTE(S) OF ADMINISTRATION**

Cattle: SC  
Pigs: IM

**5. WITHDRAWAL PERIOD**

Withdrawal period:  
Cattle: meat and offal: 15 days; milk: 5 days  
Pigs: meat and offal: 5 days

**6. BATCH NUMBER**

Lot: {number}

**7. EXPIRY DATE**

EXP: {month/year}  
Once broached use by...

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 15 mg/ml oral suspension for horses  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 15 mg/ml

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

100 ml

**5. TARGET SPECIES**

Horses

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

To be administered either mixed with food or directly into the mouth.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s):

Meat and offal: 3 days.

Not authorised for use in animals producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP {month/year}

Once broached, use within 6 months.

**11. SPECIAL STORAGE CONDITIONS**

After first opening, store below 25 °C.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only.

To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/008

**17. MANUFACTURER’S BATCH NUMBER**

Lot: {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**HDPE bottle**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 15 mg/ml oral suspension for horses  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 15 mg/ml

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

100 ml  
250 ml  
500 ml

**5. TARGET SPECIES**

Horses

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.

To be administered either mixed with food or directly into the mouth.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s):

Meat and offal: 3 days.

Not authorised for use in animals producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP {month/year}  
Once broached, use within 6 months.

**11. SPECIAL STORAGE CONDITIONS**

After first opening, store below 25 °C.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only.  
To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/008 (100 ml)  
EU/2/09/098/009 (250 ml)  
EU/2/09/098/010 (500 ml)

**17. MANUFACTURER’S BATCH NUMBER**

Lot: {number}

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET FOR:

Melovem 5 mg/ml solution for injection for cattle and pigs

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer The Netherlands

Manufacturer responsible for batch release:

Dopharma B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer The Netherlands

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 5 mg/ml solution for injection for cattle and pigs  
Meloxicam

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:

**Active substance:**

Meloxicam 5 mg

**Excipient(s):**

Benzyl alcohol 50 mg

A clear, greenish yellow solution.

### 4. INDICATION(S)

**Cattle:**

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For the relief of post-operative pain following dehorning in calves.

**Pigs:**

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For the relief of post operative pain associated with minor soft tissue surgery such as castration.

### 5. CONTRAINDICATIONS

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.  
For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.  
Do not use in pigs less than 2 days old.

## **6. ADVERSE REACTIONS**

Transient swelling at the injection site was commonly reported in clinical studies following subcutaneous administration in cattle. Injection site swelling may be painful.  
Transient swelling at the injection site was observed in clinical studies following intramuscular administration in pigs.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Cattle (calves and young cattle) and pigs.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD(S) OF ADMINISTRATION**

### **Cattle:**

Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10.0 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

### **Pigs:**

Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/25 kg body weight).

If required, a second administration of meloxicam can be given after 24 hours. It is recommended to administer the second injection at a different site since local tolerance has been assessed after single injection only.

Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.

## 10. WITHDRAWAL PERIOD

Cattle: meat and offal: 15 days.

Not permitted for use in lactating animals producing milk for human consumption.

Pigs: meat and offal: 5 days.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Keep injection vial in the outer carton in order to protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

Shelf life after first opening the container: 28 days.

Do not use this veterinary medicinal product after the expiry date (EXP) stated on the carton and bottle.

## 12. SPECIAL WARNINGS

Treatment of calves with Melovem 20 minutes before dehorning reduces post-operative pain.

Melovem alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Treatment of piglets with Melovem before castration reduces post operative pain. To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative is needed.

To obtain the best possible pain relieving effect post surgery Melovem should be administered 30 minutes before surgical intervention.

### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

### Pregnancy and lactation

Cattle: Can be used during pregnancy.

Pigs: Can be used during pregnancy and lactation.

### Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

### Overdose (symptoms, emergency procedures, antidotes):

In the case of overdosage, symptomatic treatment should be initiated.

## 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Waste materials should be disposed of in accordance with local requirements.

#### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

#### **15. OTHER INFORMATION**

Cardboard box with 1 colourless type I glass injection vial of 100 ml, which is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

## PACKAGE LEAFLET FOR

Melovem 20 mg/ml solution for injection for cattle, pigs and horses

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

#### Marketing authorisation holder

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

#### Manufacturer responsible for the batch release

Dopharma B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 20 mg/ml solution for injection for cattle, pigs and horses  
Meloxicam

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:

#### **Active substance:**

Meloxicam 20 mg

#### **Excipient(s):**

Ethanol 150 mg

A clear yellow solution.

### 4. INDICATIONS

#### **Cattle:**

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

#### **Pigs:**

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

**Horses:**

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

**5. CONTRAINDICATIONS**

Do not use in horses less than 6 weeks of age.

Do not use in pregnant or lactating mares.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

**6. ADVERSE REACTIONS**

In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.

In horses, a transient swelling at the injection site can occur but resolves without intervention.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

**7. TARGET SPECIES**

Cattle, pigs and horses

**8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION****Cattle:**

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

**Pigs:**

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.

If required, a second administration of meloxicam can be given after 24 hours.

**Horses:**

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3.0 ml/100 kg body weight).

## 9. ADVICE ON CORRECT ADMINISTRATION

Avoid introduction of contamination during use.

When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. The maximum number of broachings should be limited to 20.

## 10. WITHDRAWAL PERIOD

**Cattle:**

Meat and offal: 15 days

Milk: 5 days

**Pigs:**

Meat and offal: 5 days

**Horses:**

Meat and offal: 5 days

Not authorised to use in horses producing milk for human consumption.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Keep injection vial in the outer carton in order to protect from light.

Do not refrigerate or freeze. Protect from frost.

Shelf life after first opening the container: 28 days.

Do not use this veterinary medicinal product after the expiry date (EXP) stated on the carton and bottle.

## 12. SPECIAL WARNINGS

Treatment of calves with Melovem 20 minutes before dehorning reduces post-operative pain.

Melovem alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

Special precautions to be taken by the person administering the product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case

of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

#### Pregnancy and lactation

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: Do not use in pregnant or lactating mares.

#### Interactions with other medicinal products and other forms of interaction

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

#### Overdose (symptoms, emergency procedures, antidotes)

In the case of overdose, symptomatic treatment should be initiated.

### **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

### **15. OTHER INFORMATION**

Cardboard box with 1 colourless glass injection vial of 50 ml, 100 ml or 250 ml.  
Not all pack sizes may be marketed.

## PACKAGE LEAFLET FOR

Melovem 30 mg/ml solution for injection for cattle and pigs

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

Manufacturer responsible for the batch release

Dopharma B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
THE NETHERLANDS

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 30 mg/ml solution for injection for cattle and pigs  
Meloxicam

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

each ml contains:

**Active substance:**

Meloxicam 30 mg

**Excipient(s):**

Benzyl alcohol 20 mg  
N-Methyl pyrrolidone 200 mg

A clear yellow solution.

### 4. INDICATIONS

**Cattle:**

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

**Pigs:**

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

## 5. CONTRAINDICATIONS

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

## 6. ADVERSE REACTIONS

In cattle and pigs, subcutaneous and intramuscular administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals )
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Cattle and pigs

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

### **Cattle:**

Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/150 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

### **Pigs:**

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/150 kg body weight) in combination with antibiotic therapy, as appropriate.

If required, a second administration of meloxicam can be given after 24 hours.

## 9. ADVICE ON CORRECT ADMINISTRATION

Avoid introduction of contamination during use.

When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. The maximum number of broachings should be limited to 20.

## 10. WITHDRAWAL PERIOD

### **Cattle:**

Meat and offal: 15 days.

Milk: 5 days.

### **Pigs:**

Meat and offal: 5 days.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

Shelf life after first opening the container: 28 days.

Do not use this veterinary medicinal product after the expiry date (EXP) stated on the carton and bottle.

## 12. SPECIAL WARNINGS

Treatment of calves with Melovem 20 minutes before dehorning reduces post-operative pain.

Melovem alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

### Special precautions to be taken by the person administering the product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician. Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Women of childbearing age, pregnant women or women suspected of being pregnant should use the veterinary medicinal product with serious caution to avoid accidental self-injection.

### Pregnancy and lactation

The safety of the veterinary medicinal product has not been established in cattle and pigs during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Use only according to the benefit-risk assessment by the responsible veterinarian.

### Interactions with other medicinal products and other forms of interaction

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

### Overdose (symptoms, emergency procedures, antidotes)

In the case of overdose, symptomatic treatment should be initiated.

## 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

#### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

#### **15. OTHER INFORMATION**

Cardboard box with 1 colourless glass injection vial of 50 ml, 100 ml or 250 ml.  
Not all pack sizes may be marketed.

## PACKAGE LEAFLET

Melovem 15 mg/ml oral suspension for horses

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer The Netherlands

Manufacturer responsible for the batch release:

Dopharma B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer The Netherlands

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 15 mg/ml oral suspension for horses  
Meloxicam

### 3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS

Each ml contains:

**Active substance:**

Meloxicam 15 mg

**Excipient(s):**

Sodium benzoate 1.5 mg

Yellow, aqueous suspension.

### 4. INDICATION(S)

Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.

### 5. CONTRAINDICATIONS

Do not use in pregnant or lactating mares.

Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in horses less than 6 weeks of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 6. ADVERSE REACTIONS

Diarrhoea, typically associated with non-steroidal anti-inflammatory drugs (NSAIDs), was very rarely observed in clinical trials. The clinical sign was reversible.

Loss of appetite, lethargy, abdominal pain, colitis and urticaria have been reported very rarely from post-marketing safety experience.

Anaphylactoid reactions, which may be serious (including fatal), have been observed very rarely from post-marketing safety experience and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1 000 animals treated)
- rare (more than 1 but less than 10 animals in 10 000 animals treated)
- very rare (less than 1 animal in 10 000 animals treated, including isolated reports).

If you notice any serious effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Horses.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD(S) OF ADMINISTRATION**

To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 4 ml/100 kg body weight), once daily, up to 14 days.

## **9. ADVICE ON CORRECT ADMINISTRATION**

In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding. The suspension should be given using the measuring syringe provided in the package. The syringe has a kg-body weight scale.

Shake well before use.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIOD**

Meat and offal: 3 days.

Not authorised for use in animals producing milk for human consumption.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the container: 6 months if stored below 25 °C.

## **12. SPECIAL WARNINGS**

### Special precautions for use in animals:

Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of renal toxicity.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

### Pregnancy and lactation:

Laboratory studies in cattle have not provided any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore the use in this species is not recommended during pregnancy and lactation.

### Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

### Overdose (symptoms, emergency procedures, antidotes):

In case of overdose symptomatic treatment should be initiated.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

## **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMA) <https://www.ema.europa.eu/>.

## **15. OTHER INFORMATION**

Cardboard box with 1 bottle of 100 ml.

Bottle of 250 ml or 500 ml.

Not all pack sizes may be marketed.